The 5th Oligonucleotides for CNS Summit takes place in Boston, US on August 27-29.
Oligonucleotide-based drugs, including ASOs and siRNAs, are already significantly impacting patients’ lives. The conference will focus on drug targets amenable to modulation by oligonucleotides, recent advancements in broadening the application of oligonucleotide-based drug, including innovative approaches to ensure safety and efficacy and the use of targeted delivery to reach disease-relevant tissues, as well as clinical advancements for therapeutic oligonucleotides.
At the meeting, Cellectricon we will present a poster together with Apellis Pharmaceuticals titled:
Detection of acute and delayed onset toxicity effects of ASOs using in vitro neuronal models
If you are interested in learning more about Cellectricon’s neuroscience drug discovery services, stop by the poster or reach out to setup a meeting with our CBO, Paul Karila.
paul karila
CBO
Meet us at Oligonucleotides for CNS Summit!
We are looking forward to taking part in this year’s meeting and for the opportunity to introduce our drug discovery services to prospective new partners. Get in touch if you are interested in setting up a meeting!